Expect Exports To Grow At 25% & Domestic Biz Growth Of 20-22%: Poly Medicure | CNBC TV18

Corporate

Board of Poly Medicure appoints director

Earnings

Poly Medicure consolidated net profit rises 18.09% in the June 2024 quarter

Poly Medicure Ltd registered volume of 24.82 lakh shares by 14:14 IST on NSE, a 21.84 fold spurt over two-week average daily volume of 1.14 lakh shares

Volumes spurt at Poly Medicure Ltd counter

According to the Poly Medicure Annual Report 2023, Himanshu Baid earned nearly Rs 13 crore in compensation.

How Himanshu Baid Left High-paying Job In Germany And Built Rs 13,260 Crore Medical Devices Company - News18

For the FY23-26 period, Investec projects an Earnings before interest, depreciation, taxes and amortisation (EBIDTA) of around 29 percent and an EPS CAGR of 31 percent.

Poly Medicure shares jump 4 percent on Investec Buy rating

Poly Medicure Consolidated June 2023 Net Sales at Rs 320.83 crore, up 28.92% Y-o-Y

Poly Medicure Standalone June 2023 Net Sales at Rs 305.56 crore, up 27.85% Y-o-Y

भारत और यूरोप में अच्छी डिमांड मौजूद, इस तिमाही मौजूदा मार्जिन बरकरार रहने की उम्मीद.....इस साल 20% ग्रोथ रहने की उम्मीद : हिमांशु बैद MD, पॉली मेडिक्योर

देखिए स्वाति खंडेलवाल के साथ हिमांशु बैद ,MD, पॉली मेडिक्योर की खास बातचीत..


📺#ZeeBusiness LIVE👉https://bit.ly/46guJ2h


About Zee Business:

Zee Business is India's Number 1 Hindi business news channel. It's your channel for profit and wealth. Watch Live coverage of Indian markets - Sensex & Nifty, also for expert insights and advise from our team of experts.
 
--------------------------------------------------------------
Subscribe Zee Business: https://bit.ly/3L6GG0C
 
You Can Also Visit Our Website at: 

Zee Business: https://www.zeebiz.com/
Zee News: https://zeenews.india.com/
DNA India:-https://www.dnaindia.com/
WION: https://www.wionews.com/ 

Follow Us On: 
  
Facebook: https://goo.gl/OMJgrn
Twitter: https://goo.gl/OjOzpB 
Download Zee News App : https://bit.ly/ZeeNewsApps

Exciting Prospects: Himanshu Baid, MD of Poly Medicure, Foresees 20% Growth with Sustained Margins

Broker’s call: Poly Medicure (Buy)

On a consolidated basis, Poly Medicure’s net profit jumped 44.9% to Rs 50.01 crore on 23.7% increase in revenue from operations to Rs 284.83 crore in Q3 FY23 over Q3 FY22.

Poly Medicure Q3 PAT up 45% YoY to Rs 50 cr

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Poly Medicure Limited is engaged in the manufacturing and sale of medical devices.